Abstract
This review describes strategies used by a clinical neurologist in the investigation of neurotoxic disease. It emphasizes the need for a high level of suspicion that environmental substances are capable of producing impairments in neurologic and neurobehavioral functions. Because of the difficulties in differentiating neurotoxic from nonneurotoxic disease when presented with common neurological symptoms, it is necessary to rely upon corroborative evidence from past medical records, work and environmental histories, and exposure data, as well as detailed neurological examinations, to reach a conclusion about causation. Sensitive electrophysiologic and neuropsychologic test batteries are useful in identifying subclinical impairments and in providing objective confirmation of abnormalities in the central and peripheral nervous systems. Combining scientific and epidemiologic information with experience and clinical judgment, these sources of information are used in the formulation of a clinical diagnosis. When many patients among a group of people are exposed to neurotoxicants, the effects of the exposure may vary from one to another because of differences in susceptibility, duration of exposure and dosage of neurotoxicant, and other possible risk factors. Group statistics may obscure a significant effect for the larger group, despite clinically obvious effects in an individual. The neurologist applies clinical skills and refers to the accumulated neurotoxicologic literature as a frame of reference to make a diagnosis about an individual patient or a group of patients who have been exposed to particular neurotoxicants. The Boston University Environmental Neurology Assessment (BUENA) is a scheme that attempts to combine epidemiologic methodology and clinical approaches to detect effects of neurotoxic exposure. The advantages and limitations of such a strategy are discussed.